Biomarkers Clinical Trial
— UCD-DBDCOfficial title:
University of California (UC), Davis Dietary Biomarkers Development Center
The purpose of this research is to find a set of markers in the blood and/or urine that can be linked to consumption of specific fruits and vegetables. This will allow for better understanding of the link between diet and health-related outcomes. Furthermore, the results of this study will lead to the development of new methods to evaluate the nutritional status of individuals in both community and clinical settings. Food frequency questionnaires and diaries/recalls can be affected by intentional or unintentional misreporting, and thus can create errors in determining nutritional status. This study will lead to the development of an objective way to assess the consumption of specific fruits and vegetables by the general population.
Status | Recruiting |
Enrollment | 280 |
Est. completion date | August 31, 2026 |
Est. primary completion date | April 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Body Mass Index (BMI) 18.5-39.9 kg/m^2 - Willingness to provide urine and have blood drawn Exclusion Criteria: - Pregnancy or lactation - Allergy or aversion to foods provided in test diet - History of gastrointestinal disorders including the following: 1. Ulcerative colitis or Crohn's disease 2. Celiac sprue 3. Hereditary non-polyposis colorectal cancer (HNPCC) 4. Familial adenomatous polyposis 5. Pancreatic disease 6. Liver disease - Previous gastrointestinal resection or bariatric surgery - Bleeding disorders that preclude blood draws - Recent hospital admissions (past 6 months) for myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) - Cardiovascular disease (CVD) under physician guided therapy that is not medically stable - Cancer under radiation or chemotherapy treatment that is active or within 6 months of treatment - Weight change (± 5% in the last 3 months) - Regular alcohol intake of > 2 drinks/day (equivalent to 720 mL of beer, 240 mL of wine, or 90 mL of spirits), and unwilling to abstain during feeding periods - Use of tobacco and/or marijuana, hookahs, e-cigarettes, or vapes and not willing to abstain during feeding periods - Use of illicit drugs and not willing to abstain during feeding periods - BMI >40 kg/m^2 - Regular (daily to weekly) use of over-the-counter (OTC) weight-loss aids and unwilling or unable to stop taking these during feeding periods - Regular (daily to weekly) use of OTC anti-inflammatories and unwilling or unable to stop taking these during feeding periods - Unwilling to stop taking OTC dietary supplements that interfere with the test foods being studied including pills, chewables, liquids or powders for the following (may continue if vitamin supplement is prescribed by a medical doctor): 1. Protein supplements 2. Soy 3. Fiber 4. Flaxseed 5. Fish oil (including cod liver oil) 6. Probiotics 7. Carotenoids 8. Selenium 9. Other antioxidants 10. Other phytochemicals 11. Glucosamine 12. Chondroitin - Oral or IV antibiotic use in the past 6 months (could defer participation until 6 months post-completion of course of antibiotics) - Seated blood pressure >140/90 mmHg - Fasting clinical lab values outside of the following ranges: 1. Fasting Glucose: 54-125 mg/dL 2. Urea: 6-50 mg/dL 3. Creatinine: 0.4-1.3 mg/dL 4. Estimated Glomerular Filtration Rate (eGFR): >60 mL/min 5. Sodium: 133-146 mmol/L 6. Alanine Transaminase (ALT): 5-60 U/L 7. Aspartate Aminotransferase (AST): 5-40 U/L 8. Alkaline Phosphatase (ALP): 20-135 U/L 9. Total Bilirubin: 0.0-1.9 mg/dL 10. Total Protein: 5-9.0 g/dL 11. Albumin: 3.5-5.9 d/L 12. Low-density Lipoprotein (LDL) Cholesterol: <160 mg/dL 13. Triglycerides: <500 14. White Blood Cells: 3-10.5 Kl/µL 15. Hematocrit: 35-48 g/dL (women), 37.5-49 g/dL (men) - Current use of the following prescription medications: 1. Diuretics 2. Steroids (oral): daily oral any dose within 1 month of study (except for oral contraceptive pills) 3. Opiates: any use within 1 month of study 4. Hypolipidemic agents that affect GI or renal function (ie. fibrates) 5. Hypoglycemic medications other than metformin (ie. insulin, SGLT2 inhibitor, a-glucosidase inhibitor) 6. Psychiatric medications that affect metabolism/renal function (anti-psychotics, lithium) 7. Biologics/immune modulators (ie. rheumatoid arthritis, psoriasis, other rheumatologic/hematologic active disease) 8. Anti-coagulants (coumadin, heparin, Eliquis, etc.) 9. HIV/HAART medications (dyslipidemia inducing) - Inability to freely give informed consent |
Country | Name | City | State |
---|---|---|---|
United States | USDA ARS Western Human Nutrition Research Center | Davis | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis | USDA, Western Human Nutrition Research Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in urine metabolomics profile | Urine metabolites will be measured by ultra-performance liquid chromatography mass spectrometry (UPLC-MS) before and after consumption of no, low, or high doses of study fruits and vegetables. Change will be assessed by the appearance of and change in levels of dietary-derived metabolites, which are candidate dietary biomarkers. | Aim 1: day 3, 8, 13; overnight fasted and post prandial 0-2 hours, 2-4 hours, 4-6 hours, 6-8 hours, 8-24 hours. Aim 2: day 3, 9, 10; Aim 3: day 4. | |
Primary | Change in plasma metabolomics profile | Plasma metabolites will be measured by ultra-performance liquid chromatography mass spectrometry (UPLC-MS) before and after consumption of no, low, or high doses of study fruits and vegetables. Change will be assessed by the appearance of and change in levels of dietary-derived metabolites, which are candidate dietary biomarkers. | Aim 1: day 3, 8, 13; overnight fasted and post prandial 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 6 hour, 7 hour, 8 hour, 24 hour. Aim 2: days 3, 9, 10. Aim 3: day 4. | |
Secondary | Diet adherence | Intake of test and non-test meals/foods will be monitored through weigh-backs by study personnel in Aim 1 and participant self report in Aim 2 to identify deviations in intake of fruits/vegetables of interest. | Aim 1: day 3, 8, 13. Aim 2: day 3, 6, and 9. | |
Secondary | Habitual consumption of fruits and vegetables | 3-month General Nutrition Assessment Food Frequency Questionnaires (GNA FFQ) will be administered at site visit 1 for each aim. | Day 1 | |
Secondary | Acute consumption of fruits and vegetables | An Automated Self-Administered 24-Hour (ASA24) 3-day food record will be obtained over 2 weekdays and 1 weekend day during Aim 3. | Days 1, 2, 3. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Recruiting |
NCT05548933 -
Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia
|
||
Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
Recruiting |
NCT05372159 -
Vanderbilt Memory and Aging Project
|
||
Completed |
NCT03173586 -
Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women
|
N/A | |
Completed |
NCT04554628 -
Early Prediction of Acute Kidney Injury Among Patients Admitted to Surgical ICU
|
N/A | |
Terminated |
NCT03250312 -
The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers
|
N/A | |
Recruiting |
NCT04666766 -
Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers
|
N/A | |
Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
Completed |
NCT03193671 -
Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis
|
N/A | |
Recruiting |
NCT06047132 -
PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS
|
||
Completed |
NCT05361460 -
Patients Experiences of Early Postoperative Cognition
|
||
Recruiting |
NCT05706194 -
Early Neuroprognostication After OHCA
|
||
Recruiting |
NCT05138731 -
Metabolomics Profiling of Coronary Heart Disease
|
||
Recruiting |
NCT06446895 -
Biomarkers of Inflammation and Endothelial Dysfunction in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries
|
||
Not yet recruiting |
NCT04563000 -
Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest
|
Phase 2 | |
Completed |
NCT05138692 -
Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
|
||
Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
Active, not recruiting |
NCT02732301 -
Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers
|
||
Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A |